StockMacro
Company, fund or insider

Help

Menu

Cartesian Therapeutics

$6.14 -4.8% in 6 monthsMarket cap $187.3M

RNAC on XNAS, Health Care, Cartesian Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Net loss reached $127.5M over 12 months on $1M revenue, while cash on hand is $123M.

  • BadShort interest up 2.2% in two weeks, now 6.3% of shares

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

Industry
Pharmaceutical preparations (Health Care)
Employees
75
Website
cartesiantherapeutics.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 8 Mar 2027 (an estimate: a year ago it reported on 9 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $0, net loss $11.5M.
Quarter to 31 Dec 2021: revenue $29.9M, net income $12.2MQuarter to 31 Dec 2021: revenue $29.9M, net income $12.2MQuarter to 31 Mar 2022: revenue $34.0M, net income $28.8MQuarter to 31 Mar 2022: revenue $34.0M, net income $28.8MQuarter to 30 Jun 2022: revenue $39.3M, net income $8.6MQuarter to 30 Jun 2022: revenue $39.3M, net income $8.6MQuarter to 30 Sep 2022: revenue $20.7M, net income -$7.9MQuarter to 30 Sep 2022: revenue $20.7M, net income -$7.9MQuarter to 31 Dec 2022: revenue $16.8M, net income $5.9MQuarter to 31 Dec 2022: revenue $16.8M, net income $5.9MQuarter to 31 Mar 2023: revenue $5.9M, net income -$21.7MQuarter to 31 Mar 2023: revenue $5.9M, net income -$21.7MQuarter to 30 Jun 2023: revenue $5.2M, net income -$11.4MQuarter to 30 Jun 2023: revenue $5.2M, net income -$11.4MQuarter to 30 Sep 2023: revenue $6.6M, net income -$9.0MQuarter to 30 Sep 2023: revenue $6.6M, net income -$9.0MQuarter to 31 Dec 2023: revenue $8.3M, net income -$177.7MQuarter to 31 Dec 2023: revenue $8.3M, net income -$177.7MQuarter to 31 Mar 2024: revenue $5.8M, net income -$56.8MQuarter to 31 Mar 2024: revenue $5.8M, net income -$56.8MQuarter to 30 Jun 2024: revenue $33.4M, net income $13.8MQuarter to 30 Jun 2024: revenue $33.4M, net income $13.8MQuarter to 30 Sep 2024: revenue $387K, net income -$24.2MQuarter to 30 Sep 2024: revenue $387K, net income -$24.2MQuarter to 31 Dec 2024: revenue –, net income -$10.3MQuarter to 31 Mar 2025: revenue $1.1M, net income -$17.7MQuarter to 31 Mar 2025: revenue $1.1M, net income -$17.7MQuarter to 30 Jun 2025: revenue $298K, net income $15.9MQuarter to 30 Jun 2025: revenue $298K, net income $15.9MQuarter to 30 Sep 2025: revenue $452K, net income -$35.9MQuarter to 30 Sep 2025: revenue $452K, net income -$35.9MQuarter to 31 Dec 2025: revenue $947K, net income -$92.6MQuarter to 31 Dec 2025: revenue $947K, net income -$92.6MQuarter to 31 Mar 2026: revenue $78K, net income -$39.2MQuarter to 31 Mar 2026: revenue $78K, net income -$39.2MQuarter to 30 Jun 2026: revenue $0, net income $15.8MQuarter to 30 Jun 2026: revenue $0, net income $15.8MQuarter to 30 Sep 2026: revenue $0, net income -$11.5MQuarter to 30 Sep 2026: revenue $0, net income -$11.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $177.7M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$0-$11.5M
30 Jun 2026$0$15.8M
31 Mar 2026$78K-$39.2M
31 Dec 2025$947K-$92.6M
30 Sep 2025$452K-$35.9M
30 Jun 2025$298K$15.9M
31 Mar 2025$1.1M-$17.7M
31 Dec 2024–-$10.3M
30 Sep 2024$387K-$24.2M
30 Jun 2024$33.4M$13.8M
31 Mar 2024$5.8M-$56.8M
31 Dec 2023$8.3M-$177.7M
30 Sep 2023$6.6M-$9.0M
30 Jun 2023$5.2M-$11.4M
31 Mar 2023$5.9M-$21.7M
31 Dec 2022$16.8M$5.9M
30 Sep 2022$20.7M-$7.9M
30 Jun 2022$39.3M$8.6M
31 Mar 2022$34.0M$28.8M
31 Dec 2021$29.9M$12.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $1.0M $1.1M
Revenue growthRevenue of the last 12 months compared with the 12 months before. -6.0% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$127.5M -$48.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$4.95 $5.04
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$89.9M -$68.9M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $123.0M $143.4M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $50.2M $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$72.8M (net cash) -$143.4M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 183 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 112 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Cartesian TherapeuticsRNAC (this company) $187.3Mloss183-6.0%–
AN2 TherapeuticsANTX $192.8Mloss–––
Whitehawk TherapeuticsWHWK $181.2Mloss–––
ADC Therapeutics SAADCT $180.0Mloss1.9+13%-95.7%
Yarrow BioscienceYARW $196.5M––––
BioAge LabsBIOA $196.7Mloss22.9+45%–

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-66%

$441K vs $1.3M (quarter ended 30 Sep 2026)

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+4.2%

100 13F filers vs 96

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

29%

8.9M shares held by 13F filers (30 Sep 2026) of 30.5M outstanding (31 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

6.3%

1.9M shares sold short (30 Oct 2026) of 30.5M outstanding (31 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

16.5

1.9M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+2.2%

1.9M shares sold short in the report before, 1.9M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

67%

67% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 50%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

4

4 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

4 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $6.14 on 20 Nov 2026, -14% over 12 months (12-month range $5.84 to $10.59)

  • Sharp change
  • 8-K and other filings
  • Federal award
Insider net buying (open market). Insiders sold a net $53K in the last 12 months (the 12 months before: $3.3M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months.
Revenue per quarter. Revenue $0 in the latest quarter, -100% on a year earlier.
Capital spending per quarter. Capital spending $441K in the latest quarter, -66% on a year earlier.
Institutional holders (13F filers). 100 13F filers reported holding it in the latest 13F quarter, +49% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months, -100% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
26 May 20268-K and other filingsDirector or officer change
30 Mar 20268-K and other filingsDirector or officer change
30 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Dec 20258-K and other filingsDirector or officer change
30 Oct 20258-K and other filingsDirector or officer change
21 Oct 20258-K and other filingsDirector or officer change
8 Oct 20258-K and other filingsDirector or officer change
8 Oct 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
29 Apr 20258-K and other filingsDirector or officer change
29 Apr 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Sep 20248-K and other filingsRegistered new securities for sale (S-1)
9 Sep 20248-K and other filingsRegistered new securities for sale (S-1)
13 Aug 2024Sharp changeQuarterly revenue change: quarterly revenue change, 33.3M vs usual 7.4M (2024-06-30); 6.3x the same period a year earlier
2 Aug 20248-K and other filingsRegistered new securities for sale (S-1)
17 Jul 20248-K and other filingsPrivate placement of securities (Form D)
8 Jul 2024Federal awardnew Department of Health and Human Services grant R44NS137943 ($1.5M)
8 Jul 2024Sharp changeFirst federal award: first federal award: CARTESIAN THERAPEUTICS INC: new Department of Health and Human Services grant R44NS137943 ($1,496,118)
2 Jul 20248-K and other filingsDirector or officer change
17 Jun 20248-K and other filingsDirector or officer change
1 Apr 20248-K and other filingsDirector or officer change
14 Mar 20248-K and other filingsA major agreement ended
5 Mar 20248-K and other filingsDirector or officer change
5 Mar 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Jan 20248-K and other filingsDelisting notice or listing transfer
1 Dec 20238-K and other filingsPrivate placement of securities (Form D)
27 Nov 20238-K and other filingsDirector or officer change
13 Nov 20238-K and other filingsCompleted an acquisition or asset sale
13 Nov 20238-K and other filingsDirector or officer change
31 Oct 20238-K and other filingsDirector or officer change
25 Sep 20238-K and other filingsDirector or officer change
25 Sep 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Aug 20238-K and other filingsReport will be filed late
9 Jan 20238-K and other filingsDirector or officer change
28 Nov 20228-K and other filingsDirector or officer change
28 Nov 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Jun 20228-K and other filingsDelisting notice or listing transfer
14 Dec 2021Sharp changeClustered insider buying: clustered insider buying (4 independent filers, 4 filing(s) in 30 days, value_usd total 11.8M)
Insider net buying (open market)
Month from 1 Dec 2021: $12.3M published
Month from 1 Jan 2022: -$73K published
Month from 1 Mar 2022: -$10K published
Month from 1 Apr 2022: $0 published
Month from 1 May 2022: $38K published
Month from 1 Jun 2022: $150K published
Month from 1 Sep 2022: -$9K published
Month from 1 Oct 2022: -$4K published
Month from 1 Dec 2022: -$6K published
Month from 1 Jan 2023: -$82K published
Month from 1 Sep 2023: -$4K published
Month from 1 Mar 2024: $690K published
Month from 1 Aug 2024: $197K published
Month from 1 Oct 2024: $4.3M published
Month from 1 Nov 2024: $3.5M published
Month from 1 Dec 2024: $620K published
Month from 1 Jan 2025: -$244K published
Month from 1 Mar 2025: $1.4M published
Month from 1 Apr 2025: $1.5M published
Month from 1 Dec 2025: $206K published
Month from 1 Jan 2026: -$259K published
H-1B/E-3 applications certified
Quarter from 1 Jul 2024: 1 published
Revenue per quarter
Quarter ended 31 Dec 2021: $29.9M, +150% on a year earlier; public on 11 Mar 2022
Quarter ended 31 Mar 2022: $34.0M, +208% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $39.3M, +100% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $20.7M, -15% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $16.8M, -44% on a year earlier; public on 3 Mar 2023
Quarter ended 31 Mar 2023: $5.9M, -83% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $5.2M, -87% on a year earlier; public on 18 Aug 2023
Quarter ended 30 Sep 2023: $6.6M, -68% on a year earlier; public on 14 Nov 2023
Quarter ended 31 Dec 2023: $8.3M, -51% on a year earlier; public on 8 Mar 2024
Quarter ended 31 Mar 2024: $5.8M, -1.7% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $33.4M, +537% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $387K, -94% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Mar 2025: $1.1M, -81% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $298K, -99% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $452K, +17% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $947K; public on 10 Mar 2026
Quarter ended 31 Mar 2026: $78K, -93% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $0, -100% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $0, -100% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $278K, +46% on a year earlier; public on 11 Mar 2022
Quarter ended 31 Mar 2022: $455K, +1720% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $99K, -84% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $436K, +166% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $211K, -24% on a year earlier; public on 3 Mar 2023
Quarter ended 31 Mar 2023: $130K, -71% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $12K, -88% on a year earlier; public on 18 Aug 2023
Quarter ended 31 Dec 2023: $64K, -70% on a year earlier; public on 8 Mar 2024
Quarter ended 31 Mar 2024: $602K, +363% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $1.6M, +13125% on a year earlier; public on 9 Aug 2024
Quarter ended 31 Dec 2024: $705K, +1002% on a year earlier; public on 14 Mar 2025
Quarter ended 31 Mar 2025: $1.1M, +79% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $2.6M, +64% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $1.3M; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $492K, -30% on a year earlier; public on 10 Mar 2026
Quarter ended 31 Mar 2026: $27K, -97% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $272K, -90% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $441K, -66% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 94; public on 14 Feb 2022
31 Mar 2022 report: 92; public on 16 May 2022
30 Jun 2022 report: 87; public on 15 Aug 2022
30 Sep 2022 report: 90; public on 14 Nov 2022
31 Dec 2022 report: 80; public on 14 Feb 2023
31 Mar 2023 report: 88; public on 15 May 2023
30 Jun 2023 report: 84; public on 14 Aug 2023
30 Sep 2023 report: 77; public on 14 Nov 2023
31 Dec 2023 report: 71; public on 14 Feb 2024
31 Mar 2024 report: 67; public on 15 May 2024
30 Jun 2024 report: 61; public on 14 Aug 2024
30 Sep 2024 report: 63; public on 14 Nov 2024
31 Dec 2024 report: 67; public on 14 Feb 2025
31 Mar 2025 report: 73; public on 15 May 2025
30 Jun 2025 report: 63; public on 14 Aug 2025
30 Sep 2025 report: 67; public on 14 Nov 2025
31 Dec 2025 report: 68; public on 17 Feb 2026
31 Mar 2026 report: 82; public on 15 May 2026
30 Jun 2026 report: 96; public on 14 Aug 2026
30 Sep 2026 report: 100; public on 16 Nov 2026
Federal obligations
Month from 1 Jul 2022: $999K published
Month from 1 Sep 2022: $0 published
Month from 1 Nov 2022: $0 published
Month from 1 Jul 2024: $1.5M published
Month from 1 Sep 2024: $149K published
Month from 1 Oct 2024: $0 published
Month from 1 Jun 2025: $1.5M published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $259K (8 Jan 2026), higher than 87% of its own history.
  • Insider net buying (open market): Insiders sold a net $53K in the last 12 months (the 12 months before: $3.3M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months.
  • Revenue per quarter: Revenue $0 in the latest quarter, -100% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

No trades in the last 90 days; the latest was filed 8 Jan 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
8 Jan 2026Carsten BrunnPresident and CEOSell23,766$6.82$162KForm 4
8 Jan 2026Milos MiljkovicChief Medical OfficerSell3,573$6.82$24KForm 4
8 Jan 2026Blaine DavisChief Financial OfficerSell10,591$6.82$72KForm 4
8 Dec 2025Timothy C BarabeDirectorBuy30,000$6.86$206KForm 4
11 Apr 2025Timothy A SpringerDirector, 10% ownerBuy149,075$10.21$1.5MForm 4
20 Mar 2025Timothy A SpringerDirector, 10% ownerBuy89,863$15.26$1.4MForm 4
15 Jan 2025Timothy A SpringerDirector, 10% ownerBuy20,967$17.47$366KForm 4
7 Jan 2025Metin KurtogluChief Technology OfficerSell4,875$16.78$82KForm 4

100 institutions reported shares at the end of Q3 2026, 29% of the shares outstanding; 10 opened a position, 7 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Squarepoint Ops LLC2.3M7.42%$16.3M+8,611+0.4%
BlackRock, Inc.808K2.65%$5.8M-11K-1.3%
683 Capital Management, LLC751K2.46%$5.4M+101K+16%
Vanguard Capital Management LLC556K1.82%$4.0MNo change
FMR LLC (Fidelity)370K1.21%$2.7M+2,028+0.6%
Two Sigma Investments, LP367K1.20%$2.6M+71K+24%
Geode Capital Management, LLC343K1.12%$2.5M-14K-3.8%
AQR Capital Management LLC287K0.94%$2.1M-69K-19%
State Street Corp262K0.86%$1.9M+13K+5.0%
Marshall Wace, LLP244K0.80%$1.8M+11K+4.6%

Federal contracts

All 1 federal contracts

No new award in 12 months; the latest was signed 7 Jun 2024. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
7 Jun 2024Department of Health and Human ServicesNational Institutes of Health$3.0MMANUFACTURING RNA-BASED CAR T CELLS TO COMBAT AUTOANTIBODY-ASSOCIATED AUTOIMMUNE DISORDERS (AAAD) - AUTOANTIBODY-ASSOCIATED AUTOIMMUNE DISEASES (AAADS) ARE DISORDERS IN WHICH DYSFUNCTIONAL PLASMA CELLS (PCS) SECRETE AUTOANTIBODIES THAT ATTACK HEALTHY TISSUE. MANY AAADS ATTACK THE NERVOUS SYSTEM, SUCH AS MYASTHENIA GRAVIS (MG), NEUROMYELITIS OPTICA, CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, LAMBERT- EATON SYNDROME, AND NECROTIZING AUTOIMMUNE MYOPATHY. THIS R44 (CLINICAL TRIAL NOT ALLOWEDGrantUSAspending

Company events

All 82 company events

In 12 months: 3 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
26 May 2026Director or officer change; Signed a major agreementSame filing: took on new debt, sold shares privately8-K
30 Mar 2026Director or officer change8-K
18 Dec 2025Director or officer change8-K
30 Oct 2025Director or officer changeSame filing: changed its bylaws or fiscal year8-K
21 Oct 2025Director or officer change8-K
8 Oct 2025Director or officer change8-K
29 Apr 2025Director or officer change8-K
20 Sep 2024Registered new securities for sale (S-1)S-1/A

The 5 newest of 55 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 26 May 2026Filings record

    Director or officer change

  2. 30 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 30 Mar 2026Filings record

    Director or officer change

  4. 18 Dec 2025Filings record

    Director or officer change

  5. 9 Dec 2025Insiders record

    BARABE TIMOTHY C (director) bought 30,000 shares of RNAC ($205,800) (dated 8 Dec 2025)

  6. 30 Oct 2025Filings record

    Director or officer change

  7. 21 Oct 2025Filings record

    Director or officer change

  8. 8 Oct 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  9. 8 Oct 2025Filings record

    Director or officer change

  10. 29 Apr 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 29 Apr 2025Filings record

    Director or officer change

  12. 12 Apr 2025Insiders record

    SPRINGER TIMOTHY A (director) bought 149,075 shares of RNAC ($1.5M) (dated 11 Apr 2025)

  13. 21 Mar 2025Insiders record

    SPRINGER TIMOTHY A (director) bought 89,863 shares of RNAC ($1.4M) (dated 20 Mar 2025)

  14. 16 Jan 2025Insiders record

    SPRINGER TIMOTHY A (director) bought 20,967 shares of RNAC ($366,353) (dated 15 Jan 2025)

  15. 24 Dec 2024Insiders record

    SPRINGER TIMOTHY A (director) bought 52,189 shares of RNAC ($965,005) (dated 23 Dec 2024)

  16. 19 Nov 2024Insiders record

    SPRINGER TIMOTHY A (director) bought 431,940 shares of RNAC ($7.4M) (dated 18 Nov 2024)

  17. 5 Oct 2024Insiders record

    SPRINGER TIMOTHY A (director) bought 205,721 shares of RNAC ($4.3M) (dated 4 Oct 2024)

  18. 20 Sep 2024Filings record

    Registered new securities for sale (S-1)

  19. 9 Sep 2024Filings record

    Registered new securities for sale (S-1)

  20. 15 Aug 2024Insiders record

    SPRINGER TIMOTHY A (director) bought 8,016 shares of RNAC ($101,964) (dated 14 Aug 2024)

  21. 15 Aug 2024Insiders record

    BARABE TIMOTHY C (director) bought 7,500 shares of RNAC ($95,250) (dated 14 Aug 2024)

  22. 13 Aug 2024Financials change

    reported revenue of $33.3M for the quarter ended 30 Jun 2024, 6.3× the same quarter last year.

    Same quarter last year: $5.2M; its normal quarter is $7.4M.

    See the evidence
    This period
    $33.3M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $7.4M
    Typical spread (median absolute deviation)
    $1.9M
    How far from its usual level
    +9.4
    Same quarter last year
    $5.2M
    History used
    3,379 days
    2022-06-30: $39.3M2022-09-30: $20.7M2022-12-31: $16.8M2023-03-31: $5.9M2023-06-30: $5.2M2023-09-30: $6.6M2023-12-31: $8.3M2024-03-31: $5.8M2024-06-30: $33.3M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $7.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  23. 2 Aug 2024Filings record

    Registered new securities for sale (S-1)

  24. 17 Jul 2024Filings record

    Private placement of securities (Form D)

  25. 8 Jul 2024Government contracts change

    won its first federal award in our data, a $1.5M Department of Health and Human Services grant.

    See the evidence (1 source record)
    Source coverage starts
    7 Oct 2007
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  26. 8 Jul 2024Government contracts record

    CARTESIAN THERAPEUTICS INC: new Department of Health and Human Services grant R44NS137943 ($1.5M) (dated 7 Jun 2024)

  27. 2 Jul 2024Filings record

    Director or officer change

  28. 17 Jun 2024Filings record

    Director or officer change

  29. 1 Apr 2024Filings record

    Director or officer change

  30. 29 Mar 2024Insiders record

    SPRINGER TIMOTHY A (director) bought 18,400 shares of RNAC ($11,412) (dated 28 Mar 2024)

  31. 21 Mar 2024Insiders record

    SPRINGER TIMOTHY A (director) bought 19,044 shares of RNAC ($11,426) (dated 20 Mar 2024)

  32. 19 Mar 2024Insiders record

    SPRINGER TIMOTHY A (director) bought 1,185,872 shares of RNAC ($667,246) (dated 18 Mar 2024)

  33. 14 Mar 2024Filings record

    A major agreement ended

  34. 5 Mar 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 5 Mar 2024Filings record

    Director or officer change

  36. 19 Jan 2024Filings record

    Delisting notice or listing transfer

  37. 1 Dec 2023Filings record

    Private placement of securities (Form D)

  38. 27 Nov 2023Filings record

    Director or officer change

  39. 13 Nov 2023Filings record

    Director or officer change

  40. 13 Nov 2023Filings record

    Completed an acquisition or asset sale

Showing the newest 40 of 131 entries; narrow the window or the kind of data to see older ones.

Not listed: 222 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001453687
Ticker
RNAC
Domain
cartesiantherapeutics.com
Employer name
Cartesian Therapeutics, Inc. (1 unverified)
Fein
26-1622110 (1 unverified)
Hq location
MD|FREDERICK|21703 (1 unverified)
Name
Cartesian Bio, LLC, Cartesian Therapeutics, Inc., SELECTA BIOSCIENCES INC, Selecta (RUS) LLC
Uei
PXGLS86SY6B1
Wikidata
Q30288672
  • DOL H-1B labor condition applications and PERM certifications5 data points6 May 2024 to 6 May 2024
  • SEC Form 13F institutional holdings378 data points30 Jun 2016 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)216 records24 May 2016 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)757 data points31 Dec 2013 to 31 Oct 2026
  • SEC Form 4 insider transactions120 records, 304 data points29 Jun 2016 to 8 Jan 2026
  • FINRA short interest (twice monthly)216 data points15 Nov 2023 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1516 data points14 Nov 2023 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 48 data points1 Aug 2018 to 20 May 2025